ERVIN GRAVES STRATEGY GROUP, LLC for EMERGENT BIOSOLUTIONS INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Homeland Security HOM
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government Re-authorization of the Pandemic and All-Hazards Preparedness Act NDAA - provisions related to biological and chemical defense Department of Defense appropriations for Medical Countermeasures H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 FDA regulatory issues Issues related to Priority Review Voucher programs Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES L ERVIN | Chairman & CEO |
| MEGHAN JACKSON | — |
| COLBY MILLER | — |
Disaster Planning/Emergencies DIS
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government Re-authorization of the Pandemic and All-Hazards Preparedness Act NDAA - provisions related to biological and chemical defense Department of Defense appropriations for Medical Countermeasures H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 FDA regulatory issues Issues related to Priority Review Voucher programs Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES L ERVIN | Chairman & CEO |
| MEGHAN JACKSON | — |
| COLBY MILLER | — |
Budget/Appropriations BUD
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government Re-authorization of the Pandemic and All-Hazards Preparedness Act NDAA - provisions related to biological and chemical defense Department of Defense appropriations for Medical Countermeasures H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 FDA regulatory issues Issues related to Priority Review Voucher programs Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES L ERVIN | Chairman & CEO |
| MEGHAN JACKSON | — |
| COLBY MILLER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.